Loading
Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma.
Michael Dickinson was principal investigator and first author of the pivotal phase 2 trial of glofitamab, the CD20xCD3 bispecific antibody that produces durable complete remissions in about 40% of patients with relapsed or refractory large B-cell lymphoma after two or more lines, including after CAR-T, leading to its approval. He leads bispecific and CAR-T trials at Peter Mac and the Australasian Leukaemia and Lymphoma Group aggressive lymphoma programme.
| Title | Journal | Year |
|---|---|---|
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma | NEJM | 2022 |
| Glofitamab plus gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma (STARGLO) | Lancet | 2024 |
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific) and the tags lymphoma, bispecific.
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific).
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
Shares STARGLO, Glofitamab, CD3, CD20.
Shares Peter MacCallum Cancer Centre, CD20 and the tag australia.
Shares CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.